Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06619613
PHASE1

A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease

Sponsor: Keymed Biosciences Co.Ltd

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's disease related mild cognitive impairment and mild Alzheimer's disease.

Official title: A Randomized, Double-blind, Placebo-controlled and Multiple Dose Escalation Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease

Key Details

Gender

All

Age Range

50 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2024-11-08

Completion Date

2026-12-30

Last Updated

2025-03-19

Healthy Volunteers

No

Interventions

BIOLOGICAL

Alzheimer Disease (AD)

CM383 injection

OTHER

Placebo

Matched placebo

Locations (1)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, China